Heart disease is the number one cause of death worldwide, and women, at all ages, have higher disease mortality rates than that of men. Nour Heart’s blood-based biomarkers, Nourin protein and its regulatory miRNAs are elevated in the setting of myocardial ischemia before it progresses to infarction. Assessment of Nourin®miRNAs enables the rapid identification of a population of patients with ischemia, but without injury or infarction, and exclusion of myocardial ischemia, thus potentially improving the treatment algorithms for women.Definition:
Myocardial ischemia is defined as reduction of blood flow to heart muscle (myocardium) due to a partial or complete blockage of one or more coronary arteries. Ischemic heart disease (IHD) is characterized by the presence of myocardial ischemia in patients with coronary artery disease (CAD), unstable angina (UA), acute myocardial infarction (AMI) (heart attack), and heart failure (HF).Nourin®miRNAs:
Nour Heart, Inc. is the first to identify, patent, name, and register the tradename, Nourin®as a novel blood-based biomarker for the early detection of myocardial ischemia (in absence of cell necrosis) in cardiac patients, before progression to infarction. Nour Heart is developing Nourin miRNAs as novel blood biomarkers for early identification or exclusion of myocardial Ischemia in women suspected of having coronary artery disease.Unmet Need for Women:
Heart disease is the number one cause of death worldwide, and women, at all ages, have higher disease mortality rates than that of men. Reasons for this include: 1) unlike men with “typical” symptoms, significant numbers of women frequently present with “questionable angina”; 2) cardiovascular imaging procedures are widely used to diagnose myocardial ischemia in patients suspected of having coronary artery disease (CAD), but are limited by lack of specificity and sensitivity, particularly in women, leading to incorrectly classifying a significant percentage of women as “low-risk”; and 3) absence of a blood-based biomarker that can detect myocardial ischemia earlier than cell death, may contribute to women being under-investigated and under-treated, with worse outcomes. In fact, many women are first diagnosed with CAD at the time of unstable angina, acute myocardial infarction (heart attack), or even heart failure (HF).Nour Heart’s Strategy:
The company’s patented blood-based biomarkers, Nourin protein and its regulatory miRNAs are elevated in the setting of myocardial ischemia before it progresses to infarction. Nourin®biomarker has a strong negative predictive value enough to exclude and avoid further testing for myocardial ischemia, in the same way as NT-proBNP for heart failure and D-dimer for deep vein thrombosis. Ruling out myocardial ischemia in the majority of chest pain patients with the diagnosis of negative CAD will allow CAD-diagnosed chest pain patients to receive critical therapy, while they are still in the stable state prior to the development of irreversible damage (e.g., AMI and HF) or even death.Advantages of Nourin®miRNAs Biomarkers:
As a non-invasive and less-expensive blood-based test, Nourin®miRNAs might be used as a routine screening test to rule out the majority of negative myocardial ischemia in chest pain patients (86%) and allow CAD-diagnosed patients (14%) to receive critical therapy, while they are still in the stable state. Initiating early therapy can potentially improve patients’ outcomes, quality of life, and saving lives, and reducing the high healthcare costs.